PREPARATION OF LIPID BASED NANO CARRIERS AS DRUG DELIVERY SYSTEM FOR DIABETIC WOUND HEALING

Main Article Content

Harika Tummala
S. Jeganath

Keywords

Mupirocin, Phospholipon 90H, Cholesterol, Oxidized alginate, Gelatin

Abstract

Wound healing is a complex process involving various cellular events and molecules. Liposomal hydrogels containing therapeutic agents have emerged as a promising approach for wound healing due to their controlled drug release, improved stability, and targeted delivery. In this study, liposomal hydrogels loaded with Mupirocin and Glucophage were developed and evaluated for wound healing properties. Mupirocin prevents bacterial infections, while Glucophage promotes angiogenesis and tissue repair.


Compatibility studies using Fourier transform infrared spectroscopy and differential scanning calorimetry confirmed the compatibility of Mupirocin with excipients. A 32-factorial design was employed to optimize the liposomal formulation, resulting in formulations with a yield of 75.87%, particle size of 264.30 nm, and polydispersity index of 0.233. The formulations showed controlled drug release over 12 hours.


The liposomal hydrogels were evaluated for drug content, viscosity, water vapor transmission, fluid uptake, and rate of evaporation. In vivo studies demonstrated significant improvements in wound healing with the optimized liposomal hydrogels. Histopathological examination revealed well-structured skin and subcutaneous tissue, demonstrating their potential as effective wound dressings.


The integration of Mupirocin and Glucophage in liposomal hydrogels presents a novel therapeutic strategy for wound management. These liposomal hydrogels offer controlled drug delivery and enhanced wound healing, benefiting patients with chronic or non-healing wounds

Abstract 63 | pdf Downloads 57

References

1. Yariswamy M, Shivaprasad HV, Joshi V, Urs ANN, Nataraju A, Vishwanath BS. Topical application of serine proteases from Wrightiatinctoria R. Br. (Apocyanaceae) latex augments healing of experimentally induced excision wound in mice. J Ethnopharmacol 2013:149;377-83.
2. Lazarus GS, Cooper DM, Knighton DR, Margolis, DJ, Percoraro ER, Rodeheaver G, Robson MC.1994. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 130:489-93.
3. Moore K, McCallion R, Searle RJ, Stacey MC, Harding KG. Prediction and monitoring the therapeutic response of chronic dermal wounds. Int Wound J 2006;3:89-96.
4. Boateng JS, Matthews KH, Stevens HNE, Eccleston GM. Wound healing dressings and drug delivery systems: a review. J Pharm Sci 2008;97(8):2892-923.
5. Chaby G, Senet P, Vaneau M, Martel P, Guillaume JC, Meaume S, Teot L, et al., Dressings for acute and chronic wounds: a systematic review. Arch Dermatol 2007; 143:1297-304.
6. Dragicevic-Curic N, Winter S, Stupar M, et al. Temoporfin-loaded liposomal gels: Viscoelastic properties and in vitro skin penetration. Int J Pharm. 2009; 373:77-84.
7. Mourtas S, Haikou M, Theodoropoulou M, Tsakiroglou C, Antimisiaris SG. The effect of added liposomes on the rheological properties of a hydrogel: A systemic study. J Colloid Interf Sci 2008; 317:611-19.
8. Huang S, Fu X. Naturally derived materials-based cell and drug delivery systems in skin regeneration. J Control Release 2010; 142:149-59
9. Thu H, Zulfakar MH, Shiow-Fern Ng. Alginate based bilayer hydrocolloid films as potential slow-release modern wound dressing. Int J Pharm. 2012; 434:375-83.
10. Boanini E, Rubini K, Panzavolta S, Bigi A. Chemico-physical characterization of gelatin films modified with oxidized alginate. Acta Biomater 2010; 6:383-8.
11. Pappa KA. The clinical development of mupirocin. J Am Acad Dermatol. 1990; 22:873-9.
12. Ward A, Campoli-Richards DM. Mupirocin: review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 32:425-44.
13. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-9.
14. Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chemother 1990;25 Suppl B:1-5.
15. Bishop EJ, Howden BP. Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions. Expert Opin Emerg Drugs 2007; 12:1-22.
16. Stringel G, Bawdon R, Savrich M, Guertin L, Horton J. Topical and systemic antibiotics in the prevention of wound infection. J Pediatr Surg 1989; 24:1003-6.